TY - JOUR
T1 - Electronic Inhaler Monitoring for Chronic Airway Disease
T2 - Development and Application of a Multidimensional Efficacy Framework
AU - Tay, Tunn Ren
AU - van Boven, Job F.M.
AU - Chan, Amy
AU - Hew, Mark
N1 - Funding Information:
Conflicts of interest: T.R. Tay has received speaker fees from AstraZeneca and Sanofi, paid to her institution. J.F.M. van Boven reports grants from AstraZeneca; grants and personal fees from Boehringer Ingelheim, Chiesi, and Trudell Medical; and personal fees from GSK, Menarini, Novartis, and Teva, outside the submitted work; and has received funding from the European Commission to chair the European Network to Advance Best Practices and Technology on Medication Adherence (COST Action CA19132, ENABLE). All were paid to his institution. A.H.Y. Chan is director of AHYC Consultancy Ltd, providing freelance consultancy to a UCL Business company (Spoonful of Sugar Ltd); she has received research grants from A+ Charitable Trust, Universitas 21, New Zealand Pharmacy Education Research Fund, Auckland Academic Health Alliance, Asthma UK, University of Auckland, Health Research Council, Oakley Mental Health Research Foundation, and Chorus. She has received fellowship funding from the Robert Irwin Postdoctoral Fellowship, as well as travel grants from Maurice Phyllis Paykel Trust and Asthma Respiratory Foundation NZ. She is also an unpaid advisory board member for Health Navigator Advisory Board and Asthma New Zealand. M. Hew has received grants, speaker fees, and advisory board payments from GlaxoSmithKline, AstraZeneca, Novartis, Teva, Sanofi, and Seqirus, all paid to his institutional employer, Alfred Health.
Funding Information:
Conflicts of interest: T.R. Tay has received speaker fees from AstraZeneca and Sanofi, paid to her institution. J.F.M. van Boven reports grants from AstraZeneca; grants and personal fees from Boehringer Ingelheim, Chiesi, and Trudell Medical; and personal fees from GSK, Menarini, Novartis, and Teva, outside the submitted work; and has received funding from the European Commission to chair the European Network to Advance Best Practices and Technology on Medication Adherence (COST Action CA19132, ENABLE). All were paid to his institution. A.H.Y. Chan is director of AHYC Consultancy Ltd, providing freelance consultancy to a UCL Business company (Spoonful of Sugar Ltd); she has received research grants from A+ Charitable Trust, Universitas 21, New Zealand Pharmacy Education Research Fund, Auckland Academic Health Alliance, Asthma UK, University of Auckland, Health Research Council, Oakley Mental Health Research Foundation, and Chorus. She has received fellowship funding from the Robert Irwin Postdoctoral Fellowship, as well as travel grants from Maurice Phyllis Paykel Trust and Asthma Respiratory Foundation NZ. She is also an unpaid advisory board member for Health Navigator Advisory Board and Asthma New Zealand. M. Hew has received grants, speaker fees, and advisory board payments from GlaxoSmithKline, AstraZeneca, Novartis, Teva, Sanofi, and Seqirus, all paid to his institutional employer, Alfred Health.
Publisher Copyright:
© 2021 American Academy of Allergy, Asthma & Immunology
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Inhaled therapy is the cornerstone of chronic airway disease therapy, but poor adherence to controller inhalers worsens clinical outcomes and increases cost. Monitoring of controller use is needed to improve adherence, and monitoring of reliever use can predict impending exacerbations. Both can be accurately achieved by electronic inhaler monitoring (EIM). However, evidence for EIM use in clinical practice is limited and varied, and knowledge gaps remain across different outcomes and health settings. We aimed to develop a framework to assess EIM systematically across all aspects of efficacy, apply this framework to the current literature, and identify gaps in efficacy to inform future development in the field. We adapted an existing framework for diagnostic tests, consisting of six levels of efficacy with ascending clinical relevance: technical, diagnostic accuracy, diagnostic thinking, therapeutic, patient outcome, and societal efficacy. Tailoring this framework to EIM, we incorporated expert feedback and applied it to the EIM efficacy literature. We found that EIM has good diagnostic accuracy, diagnostic thinking, and therapeutic efficacies, but evidence is lacking for specific aspects of technical, patient outcome, and societal efficacies. Further development of EIM requires improved reliability, usability, and data security for patients, and optimal integration with electronic medical records and overall patient care. Defining appropriate target patient groups and pairing EIM data with effective interventions, in conjunction with reducing costs through technological innovation and economies of scale, will enhance patient and societal outcome efficacies.
AB - Inhaled therapy is the cornerstone of chronic airway disease therapy, but poor adherence to controller inhalers worsens clinical outcomes and increases cost. Monitoring of controller use is needed to improve adherence, and monitoring of reliever use can predict impending exacerbations. Both can be accurately achieved by electronic inhaler monitoring (EIM). However, evidence for EIM use in clinical practice is limited and varied, and knowledge gaps remain across different outcomes and health settings. We aimed to develop a framework to assess EIM systematically across all aspects of efficacy, apply this framework to the current literature, and identify gaps in efficacy to inform future development in the field. We adapted an existing framework for diagnostic tests, consisting of six levels of efficacy with ascending clinical relevance: technical, diagnostic accuracy, diagnostic thinking, therapeutic, patient outcome, and societal efficacy. Tailoring this framework to EIM, we incorporated expert feedback and applied it to the EIM efficacy literature. We found that EIM has good diagnostic accuracy, diagnostic thinking, and therapeutic efficacies, but evidence is lacking for specific aspects of technical, patient outcome, and societal efficacies. Further development of EIM requires improved reliability, usability, and data security for patients, and optimal integration with electronic medical records and overall patient care. Defining appropriate target patient groups and pairing EIM data with effective interventions, in conjunction with reducing costs through technological innovation and economies of scale, will enhance patient and societal outcome efficacies.
KW - Adherence
KW - Asthma
KW - COPD
KW - Digital health
KW - Dose count
KW - Inhaler
UR - http://www.scopus.com/inward/record.url?scp=85122019473&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.11.027
DO - 10.1016/j.jaip.2021.11.027
M3 - Article
C2 - 34915225
AN - SCOPUS:85122019473
SN - 2213-2198
VL - 10
SP - P1189-1201.E1
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 5
ER -